AMTI - Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data

• Shares of Applied Molecular Transport ( NASDAQ: AMTI ) are up ~4% in after-hours trading after the company said it will release top-line results from a phase 2 trial of AMT-101 for ulcerative colitis before Wednesday's opening bell.
• The trial enrolled biologic-naive patients with moderate-to-severe disease. AMT-101 was given with a TNF? inhibitor.
• AMT-101 is a GI-selective, oral recombinant biologic fusion protein of human interleukin 10 (hIL-10).
• In May, Applied Molecular implemented a cost and workforce cutting plan .

For further details see: